Navigation Links
Multigene Test Predicts Who Could Avoid Chemotherapy Despite Positive Lymph Nodes in Early Breast Cancer
Date:12/13/2007

SAN ANTONIO, Texas, Dec. 13 /PRNewswire/ -- Kathy S. Albain, MD, of Loyola University Chicago, presented new data showing for the first time the predictive value of the 21-gene Recurrence Score (RS) assay in patients with node-positive breast cancer. The Breast Cancer Intergroup of North America trial conducted by the Southwest Oncology Group (SWOG 8814) originally showed that patients treated with 6 cycles of chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil followed by 5 years of tamoxifen (CAF-T) had superior disease-free survival (DFS) and overall survival (OS) compared with patients treated with tamoxifen alone. This RS assay was performed on the breast cancer tumor specimens collected on this trial, and measured the same groups of genes already in use to predict outcomes and chemotherapy benefit in lymph node-negative disease. Up until this study, standard practice was to give chemotherapy to women with positive nodes. This study sought to determine if the RS assay would be useful to predict who might avoid chemotherapy.

Dr Albain's group first showed that the RS is prognostic for 10-year DFS and OS in patients treated with tamoxifen alone. They then compared DFS in patients treated with tamoxifen versus patients treated with CAF-T across RSs. They found that there was a large and significant benefit in DFS over 10 years from adding CAF in patients with a high RS. In contrast, there was no benefit in patients with a low RS. Interaction between CAF benefit and the linear RS was significant overall and in the first 5 years. There was a strong carryover benefit of CAF in high RSs out to 10 years, but no effect whatsoever in low RSs long term. This interaction of RS with treatment effect was true in greater than or equal to 4 positive nodes and 1 to 3 positive nodes.

In summary, this work demonstrates that: (1) a very strong benefit from chemotherapy with CAF is predicted when the RS is high, and that (2) a low RS may define a group of women with positive nodes who do not appear to benefit from anthracycline-based chemotherapy.

Dr Albain concluded, "These data collectively challenge chemotherapy mandates for patients with node-positive, ER-positive disease: not all benefit from chemotherapy, whereas others derive greater benefit than previously predicted. SWOG 8814 joins a suite of studies that provide a consistent message regarding the value of the RS for individualized adjuvant therapy, and for the first time shows its value in a population of women with node-positive breast cancer who were treated with a tamoxifen-alone control. These findings should be discussed with women diagnosed with early breast cancer who fit the criteria for this study."


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The next generation: nanomagnets could replace semiconductors
2. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
3. Nanotech could make solar energy as easy and cheap as growing grass
4. Bone-growing nanomaterial could improve orthopaedic implants
5. Stem Cell Breakthrough Could End Human Embryonic Experimentation
6. FED-TVs with carbon nanotube technology could supersede plasma and LCD flat screens
7. Blue dye could hold the key to super processing power
8. ORNL super water repellent could cause big wave in market
9. Tethered to chip, energy supply that drives sperm could power nanobot
10. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder ... several positive developments that position the Company for the future. Kinder Scientific ... Craig F. Kinghorn has been appointed Chairman of the Board, Curtis D. Kinghorn ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... recently became double board-certified in surgery and surgery of the hand by the ... is no stranger to going above and beyond in his pursuit of providing ...
(Date:5/25/2016)... New Haven, Connecticut (PRWEB) , ... May 25, ... ... today that the U.S. Food and Drug Administration (FDA) has granted the company’s ... This is the company’s second orphan drug designation granted by the FDA. ...
(Date:5/23/2016)... ... 23, 2016 , ... The need for blood donations in South Texas and across the nation ... Blood & Tissue Center, blood donations are on the decline. In fact, donations across the ... 21 percent in South Texas in the last four years alone. , There is no ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
Breaking Biology News(10 mins):